-DOCSTART- -X- O
Background. -X- _ O
Chronic -X- _ B-Patient
lung -X- _ I-Patient
allograft -X- _ I-Patient
dysfunction -X- _ I-Patient
( -X- _ I-Patient
CLAD -X- _ I-Patient
) -X- _ I-Patient
is -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
allograft -X- _ O
loss -X- _ O
post-lung -X- _ O
transplantation. -X- _ O
Prior -X- _ O
studies -X- _ O
have -X- _ O
examined -X- _ O
the -X- _ O
association -X- _ O
between -X- _ O
respiratory -X- _ B-Intervention
virus -X- _ I-Intervention
infection -X- _ I-Intervention
( -X- _ I-Intervention
RVI -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ O
CLAD -X- _ B-Patient
were -X- _ O
limited -X- _ O
by -X- _ O
older -X- _ O
diagnostic -X- _ O
techniques -X- _ O
, -X- _ O
study -X- _ O
design -X- _ O
, -X- _ O
and -X- _ O
case -X- _ O
numbers. -X- _ O
We -X- _ O
examined -X- _ O
the -X- _ O
association -X- _ O
between -X- _ O
symptomatic -X- _ B-Intervention
RVI -X- _ I-Intervention
and -X- _ O
CLAD -X- _ B-Patient
using -X- _ O
modern -X- _ O
diagnostic -X- _ O
techniques -X- _ O
in -X- _ O
a -X- _ O
large -X- _ O
contemporary -X- _ O
cohort -X- _ O
of -X- _ O
lung -X- _ O
transplant -X- _ B-Patient
recipients -X- _ I-Patient
( -X- _ I-Patient
LTRs -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Methods. -X- _ O
We -X- _ O
retrospectively -X- _ O
assessed -X- _ O
clinical -X- _ O
variables -X- _ O
including -X- _ O
acute -X- _ O
rejection -X- _ O
, -X- _ O
cytomegalovirus -X- _ O
pneumonia -X- _ O
, -X- _ O
upper -X- _ O
and -X- _ O
lower -X- _ O
RVI -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
primary -X- _ O
endpoint -X- _ O
of -X- _ O
CLAD -X- _ O
( -X- _ O
determined -X- _ O
by -X- _ O
2 -X- _ O
independent -X- _ O
reviewers -X- _ O
) -X- _ O
in -X- _ O
250 -X- _ O
LTRs -X- _ O
in -X- _ O
a -X- _ O
single -X- _ O
university -X- _ O
transplantation -X- _ O
program. -X- _ O
Univariate -X- _ O
and -X- _ O
multivariate -X- _ O
Cox -X- _ O
models -X- _ O
were -X- _ O
used -X- _ O
to -X- _ O
analyze -X- _ O
the -X- _ O
relationship -X- _ O
between -X- _ O
RVI -X- _ O
and -X- _ O
CLAD -X- _ O
in -X- _ O
a -X- _ O
time-dependent -X- _ O
manner -X- _ O
, -X- _ O
incorporating -X- _ O
different -X- _ O
periods -X- _ O
of -X- _ O
risk -X- _ O
following -X- _ O
RVI -X- _ O
diagnosis. -X- _ O
Results. -X- _ O
Fifty -X- _ B-Intervention
patients -X- _ I-Intervention
( -X- _ I-Intervention
20 -X- _ I-Intervention
% -X- _ I-Intervention
) -X- _ I-Intervention
were -X- _ I-Intervention
diagnosed -X- _ I-Intervention
with -X- _ I-Intervention
CLAD -X- _ I-Intervention
at -X- _ O
a -X- _ O
median -X- _ O
of -X- _ O
95 -X- _ O
weeks -X- _ O
post-transplantation -X- _ O
, -X- _ O
and -X- _ O
79 -X- _ B-Outcome
( -X- _ I-Outcome
32 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
114 -X- _ I-Outcome
episodes -X- _ I-Outcome
of -X- _ I-Outcome
RVI. -X- _ I-Outcome
In -X- _ O
multivariate -X- _ O
analysis -X- _ O
, -X- _ O
rejection -X- _ B-Outcome
and -X- _ I-Outcome
RVI -X- _ I-Outcome
were -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
CLAD -X- _ I-Outcome
( -X- _ I-Outcome
adjusted -X- _ I-Outcome
hazard -X- _ I-Outcome
ratio -X- _ I-Outcome
[ -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
] -X- _ I-Outcome
) -X- _ I-Outcome
2.2 -X- _ I-Outcome
( -X- _ I-Outcome
1.2–3.9 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.01 -X- _ I-Outcome
and -X- _ I-Outcome
1.9 -X- _ I-Outcome
( -X- _ I-Outcome
1.1–3.5 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.03 -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
The -X- _ I-Outcome
association -X- _ I-Outcome
of -X- _ I-Outcome
RVI -X- _ I-Outcome
with -X- _ I-Outcome
CLAD -X- _ I-Outcome
was -X- _ I-Outcome
stronger -X- _ I-Outcome
the -X- _ I-Outcome
more -X- _ I-Outcome
proximate -X- _ I-Outcome
the -X- _ I-Outcome
RVI -X- _ I-Outcome
episode -X- _ I-Outcome
: -X- _ I-Outcome
4.8 -X- _ I-Outcome
( -X- _ I-Outcome
1.9–11.6 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.01 -X- _ I-Outcome
; -X- _ I-Outcome
3.4 -X- _ I-Outcome
( -X- _ I-Outcome
1.5–7.5 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.01 -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
2.4 -X- _ I-Outcome
( -X- _ I-Outcome
1.2–5.0 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.02 -X- _ I-Outcome
in -X- _ I-Outcome
multivariate -X- _ I-Outcome
analysis -X- _ I-Outcome
for -X- _ I-Outcome
3 -X- _ I-Outcome
, -X- _ I-Outcome
6 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
12 -X- _ I-Outcome
months -X- _ I-Outcome
following -X- _ I-Outcome
RVI -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
Conclusions. -X- _ O
Symptomatic -X- _ B-Patient
RVI -X- _ I-Patient
is -X- _ I-Patient
independently -X- _ I-Patient
associated -X- _ I-Patient
with -X- _ I-Patient
development -X- _ I-Patient
of -X- _ I-Patient
CLAD -X- _ I-Patient
, -X- _ I-Patient
with -X- _ I-Patient
increased -X- _ I-Patient
risk -X- _ I-Patient
at -X- _ I-Patient
shorter -X- _ I-Patient
time -X- _ I-Patient
periods -X- _ I-Patient
following -X- _ I-Patient
RVI. -X- _ I-Patient
Prospective -X- _ O
studies -X- _ O
to -X- _ O
characterize -X- _ O
the -X- _ O
virologic -X- _ O
determinants -X- _ O
of -X- _ O
CLAD -X- _ O
and -X- _ O
define -X- _ O
the -X- _ O
underlying -X- _ O
mechanisms -X- _ O
are -X- _ O
warranted -X- _ O
. -X- _ O

